Clinical Trial Update: Clinical Efficacy of PRO-118 Compared With Olopatadine Hydrochloride Ophthalmic Solution in Allergic Conjunctivitis [Phase 3]

View source ↗

Summary

Phase 3 clinical trial comparing PRO-118 to olopatadine for allergic conjunctivitis was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Allergic Conjunctivitis

Drugs mentioned

• OLOPATADINE HYDROCHLORIDE OPHTHALMIC SOLUTION (olopatadine hydrochloride ophthalmic solution)
• PRO-118 (PRO-118)

Snippet

Sponsor: Laboratorios Sophia S.A de C.V. | Conditions: Allergic Conjunctivitis | Phase 3 | Status: WITHDRAWN